The European Alliance for Responsible Research & Development and Affordable Medicines (of which SOMO is a member) wrote a letter to the European Commission to express our concern about the next EU Health Private-Public Partnership….
The total control of drug development by pharmaceutical companies is both problematic and unsustainable. Pharmaceutical companies are often more concerned about profits than public health priorities or corporate accountability.
As a result, key health priorities are neglected and people lack access to the medicine they need. Companies engage in harmful and unethical research practices, and irresponsible marketing practices.
SOMO researches the policies and practices around pharmaceutical drug development, with a particular focus on the ethics of drug testing in low and middle income countries. Clinical trials in these countries often involve vulnerable people, raising serious ethical questions.
We push pharmaceutical companies to act with due diligence in line with the UN Guiding Principles on Business and Human Rights in relation to peoples’ participation in clinical trials, as well as Post-Trial Access (PTA) to medicine.read more less